# KEYNOTE-045 (NCT02256436)

> A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: recurrent or progressive metastatic urothelial cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02256436
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Urothelial Cancer
- Interventions: pembrolizumab; paclitaxel; vinflunine; docetaxel
- Enrollment: 542
- Primary outcome: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - All Participants
- Primary outcome: Overall Survival (OS) - All Participants
- Primary outcome: PFS Per RECIST 1.1 - Participants With Programmed Cell Death-Ligand (PD-L1) Positive Tumors
- Primary outcome: OS - Participants With PD-L1 Positive Tumors
- Primary outcome: PFS Per RECIST 1.1 - Participants With Strongly PD-L1 Positive Tumors
- Primary outcome: OS - Participants With Strongly PD-L1 Positive Tumors

## Questions raised in the commentary

_Automated from the 30 newest of 35 indexed sources (May 2017 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether PD-L1 can predict pembrolizumab benefit
- Whether pembrolizumab retreatment is appropriate after prior benefit
- Which subsequent treatments to consider after pembrolizumab

## Indexed commentary on KEYNOTE-045 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 22
- Podcasts: 8
- YouTube: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-045-nct02256436

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02256436", "email": "<work email>"}; the inbox owner confirms by the emailed link.